Alexion Pharmaceuticals Inc. has completed its acquisition of Synageva BioPharma Corp. The transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.
“As we complete this acquisition, the combination of our two companies provides us the exciting opportunity to build upon our collective strengths and talents to firmly establish Alexion as the global leader in serving patients with devastating and rare diseases,” said David Hallal, CEO at Alexion. “With Soliris, and the anticipated approvals of Strensiq and Kanuma, Alexion is poised to have three innovative products serving patients with four severe diseases in 2015 while also advancing the deepest and broadest pipeline in our history.”
According to a press release, Kanuma is currently under Priority Review with the FDA and has been granted accelerated assessment of its Marketing Authorization Application (MAA) by the EMA. Regulatory decisions in the U.S. and Europe are expected in the second half of 2015.
Alexion now has eight product candidates in clinical trials for 11 indications, the release said. Additionally, the combined preclinical pipeline includes more than 30 diverse programs across a range of therapeutic modalities, with at least four additional programs to enter the clinic in 2016.
Read the full release